Key facts
- Vectiopep’s last known valuation is $3.0M (Apr 2024).
- It has raised $460K; the latest was Early Stage VC in Jan 2025.
- Notable investors include Sofigama Investments, Dag Nurm, Ivo Remmelg, Missouri Innovation Center, Tartu TaeduPark — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Vectiopep
- ·The full record, as it builds
Funding rounds
No funding rounds for Vectiopep are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vectiopep
Operator of a biotechnology company intended to develop cancer immunotherapies. The company develops tissue-specific RNA delivery technologies using peptide-based carriers combined with mRNA therapeutics to target immune cells, enabling patients to activate their immune system to fight cancer.
- Sector
- Healthcare
- HQ
- Tartu, Estonia
- Founded
- 2022
- Employees
- 6
- Website
- vectiopep.ee/
- Ownership
- Privately Held (backing)
Vectiopep doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vectiopep shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vectiopep in its N-PORT filings yet. We sweep new filings monthly.